Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

• Results Overview

  Once-daily oral abrocitinib (200mg or 100mg) significantly improved eczema symptoms compared to placebo in adolescents and adults with moderate-to-severe atopic dermatitis, with improvements seen as early as 2 weeks into treatment.

• Study Summary

  Num Participants:

  391

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'IGA response': 38.1, 'EASI-75': 61.0, 'PP-NRS response': 55.3}

  Efficacy End Points Control:

  {'IGA response': 9.1, 'EASI-75': 10.4, 'PP-NRS response': 11.5}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nausea	Low	14.2
  Acne	Low	5.8
  Vomiting	Low	5.2

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Dermatitis Atopic	Medium	15.4